X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Substance Abuse Treatment Companies

This report lists the top Substance Abuse Treatment companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Substance Abuse Treatment industry.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Substance Abuse Treatment Top Companies

  1. Alkermes

  2. Mallinckrodt Pharmaceuticals

  3. Cipla

  4. GlaxoSmithKline

  5. Indivior

*Disclaimer: Top companies sorted in no particular order

Substance Abuse Treatment Market Major Players

Substance Abuse Treatment Market Concentration

Substance Abuse Treatment  Market Concentration

Substance Abuse Treatment Company List

                            • Alkermes PLC

                            • Cipla Ltd

                            • GlaxoSmithKline PLC

                            • Mallinckrodt LLC

                            • Indivior PLC

                            • Pfizer Inc.

                            • Teva Pharmaceutical Industries Ltd

                            • Orexo AB

                            • Apotex

                            • Opiant Pharmaceuticals Inc.

                            • Apotex

                            • BioCorRx Inc.

                            • Opiant Pharmaceuticals Inc.

                            • Purdue Pharma LP

                            • Novartis AG (Sandoz)


                        Specific to Substance Abuse Treatment Market
                        Need More Details On Market Players And Competitors?
                        Download PDF

                        Substance Abuse Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)